vs
ANI PHARMACEUTICALS INC（ANIP）与Fiverr International Ltd.（FVRR）财务数据对比。点击上方公司名可切换其他公司
Fiverr International Ltd.的季度营收约是ANI PHARMACEUTICALS INC的1.2倍（$287.8M vs $247.1M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 1.9%，领先9.2%），Fiverr International Ltd.自由现金流更多（$52.1M vs $29.1M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 29.5%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Fiverr International Ltd.运营全球在线自由职业服务平台，连接160余个国家的企业客户与独立创作者，提供数字营销、平面设计、编程、文案撰写、视频剪辑等多领域专业服务，满足各类客户灵活的按需用工需求。
ANIP vs FVRR — 直观对比
营收规模更大
FVRR
是对方的1.2倍
$247.1M
净利率更高
ANIP
高出9.2%
1.9%
自由现金流更多
FVRR
多$22.9M
$29.1M
两年增速更快
ANIP
近两年复合增速
29.5%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $287.8M |
| 净利润 | $27.5M | $5.4M |
| 毛利率 | — | 82.5% |
| 营业利润率 | 14.1% | -3.5% |
| 净利率 | 11.1% | 1.9% |
| 营收同比 | 29.6% | — |
| 净利润同比 | 367.5% | — |
| 每股收益（稀释后） | $1.14 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPFVRR
| Q4 25 | $247.1M | — | ||
| Q3 25 | $227.8M | $287.8M | ||
| Q2 25 | $211.4M | $188.2M | ||
| Q1 25 | $197.1M | $93.5M | ||
| Q4 24 | $190.6M | — | ||
| Q3 24 | $148.3M | $269.9M | ||
| Q2 24 | $138.0M | $177.3M | ||
| Q1 24 | $137.4M | $88.0M |
净利润ANIPFVRR
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $5.4M | ||
| Q2 25 | $8.5M | $4.1M | ||
| Q1 25 | $15.7M | $788.0K | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $-1.0M | ||
| Q2 24 | $-2.3M | $-4.0M | ||
| Q1 24 | $18.2M | $-4.3M |
毛利率ANIPFVRR
| Q4 25 | — | — | ||
| Q3 25 | — | 82.5% | ||
| Q2 25 | — | 83.3% | ||
| Q1 25 | — | 83.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 82.8% | ||
| Q2 24 | — | 82.4% | ||
| Q1 24 | — | 82.2% |
营业利润率ANIPFVRR
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.9% | -3.5% | ||
| Q2 25 | 6.6% | -3.4% | ||
| Q1 25 | 13.3% | -4.4% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -13.8% | -5.0% | ||
| Q2 24 | 3.7% | -6.3% | ||
| Q1 24 | 14.8% | -8.1% |
净利率ANIPFVRR
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | 1.9% | ||
| Q2 25 | 4.0% | 2.2% | ||
| Q1 25 | 8.0% | 0.8% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | -0.4% | ||
| Q2 24 | -1.7% | -2.3% | ||
| Q1 24 | 13.2% | -4.9% |
每股收益（稀释后）ANIPFVRR
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | — | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | — | ||
| Q2 24 | $-0.14 | — | ||
| Q1 24 | $0.82 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $133.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $362.6M |
| 总资产 | $1.4B | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPFVRR
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | $133.5M | ||
| Q2 25 | $217.8M | $578.4M | ||
| Q1 25 | $149.8M | $133.5M | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | $183.7M | ||
| Q2 24 | $240.1M | $183.7M | ||
| Q1 24 | $228.6M | $183.7M |
股东权益ANIPFVRR
| Q4 25 | $540.7M | — | ||
| Q3 25 | $505.8M | $362.6M | ||
| Q2 25 | $436.8M | $404.9M | ||
| Q1 25 | $418.6M | $362.6M | ||
| Q4 24 | $403.7M | — | ||
| Q3 24 | $405.9M | $355.8M | ||
| Q2 24 | $455.8M | $355.8M | ||
| Q1 24 | $452.0M | $355.8M |
总资产ANIPFVRR
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $1.1B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | $1.0B | ||
| Q2 24 | $920.8M | $1.0B | ||
| Q1 24 | $914.5M | $1.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $53.0M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $52.1M |
| 自由现金流率自由现金流/营收 | 11.8% | 18.1% |
| 资本支出强度资本支出/营收 | 0.5% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.10× | 9.81× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $124.9M |
8季度趋势，按日历期对齐
经营现金流ANIPFVRR
| Q4 25 | $30.4M | — | ||
| Q3 25 | $44.1M | $53.0M | ||
| Q2 25 | $75.8M | $42.2M | ||
| Q1 25 | $35.0M | $21.2M | ||
| Q4 24 | $15.9M | — | ||
| Q3 24 | $12.5M | $10.9M | ||
| Q2 24 | $17.4M | $32.2M | ||
| Q1 24 | $18.3M | $21.2M |
自由现金流ANIPFVRR
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | $52.1M | ||
| Q2 25 | $71.8M | $41.5M | ||
| Q1 25 | $32.5M | $20.8M | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | $10.6M | ||
| Q2 24 | $13.0M | $31.5M | ||
| Q1 24 | $13.7M | $20.8M |
自由现金流率ANIPFVRR
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | 18.1% | ||
| Q2 25 | 34.0% | 22.0% | ||
| Q1 25 | 16.5% | 22.3% | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | 3.9% | ||
| Q2 24 | 9.4% | 17.8% | ||
| Q1 24 | 10.0% | 23.7% |
资本支出强度ANIPFVRR
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | 0.3% | ||
| Q2 25 | 1.9% | 0.4% | ||
| Q1 25 | 1.3% | 0.4% | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | 0.1% | ||
| Q2 24 | 3.2% | 0.4% | ||
| Q1 24 | 3.3% | 0.4% |
现金转化率ANIPFVRR
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 9.81× | ||
| Q2 25 | 8.87× | 10.40× | ||
| Q1 25 | 2.23× | 26.90× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
FVRR
暂无分部数据
